新型冠状病毒肺炎感染过程中的血小板减少症
Thrombocytopenia in the Course of COVID-19 Infection.
作者信息
Lorenzo-Villalba Noel, Zulfiqar Abrar-Ahmad, Auburtin Marc, Schuhmacher Marie Helene, Meyer Alain, Maouche Yasmine, Keller Olivier, Andres Emmanuel
机构信息
Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasboug, Strasbourg France.
Service de Médecine Interne, Centre Hospitalier d'Epinal, Epinal, France.
出版信息
Eur J Case Rep Intern Med. 2020 May 7;7(6):001702. doi: 10.12890/2020_001702. eCollection 2020.
Abstract
UNLABELLED
We report three cases of severe thrombocytopenia during COVID-19 infection associated with either cutaneous purpura or mucosal bleeding. The initial investigations ruled out other causes of thrombocytopenia. Two of the patients were treated with intravenous immunoglobulins and eltrombopag, while the third recovered spontaneously. A good clinical and biological response was achieved in all patients leading to hospital discharge.
LEARNING POINTS
Immune thrombocytopenia should be considered in COVID-19-infected patients presenting with thrombocytopenia.Coronavirus-related thrombocytopenia can be severe and life-threatening.Despite the severity of coronavirus-related immune thrombocytopenia, recovery may be spontaneous or achieved following immunoglobulin or platelet growth factor administration.
摘要
未标注
我们报告了3例新型冠状病毒肺炎（COVID-19）感染期间出现严重血小板减少症的病例，伴有皮肤紫癜或黏膜出血。初步检查排除了血小板减少症的其他病因。其中2例患者接受了静脉注射免疫球蛋白和艾曲泊帕治疗，而第3例患者自行康复。所有患者均取得了良好的临床和生物学反应，得以出院。
学习要点
对于出现血小板减少症的COVID-19感染患者，应考虑免疫性血小板减少症。冠状病毒相关的血小板减少症可能很严重，甚至危及生命。尽管冠状病毒相关的免疫性血小板减少症很严重，但恢复情况可能是自发的，或在给予免疫球蛋白或血小板生长因子后实现。
相似文献
1
Thrombocytopenia in the Course of COVID-19 Infection.新型冠状病毒肺炎感染过程中的血小板减少症
Eur J Case Rep Intern Med. 2020 May 7;7(6):001702. doi: 10.12890/2020_001702. eCollection 2020.
2
Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial.免疫性血小板减少症患者围手术期口服艾曲泊帕与静脉注射免疫球蛋白的比较：一项非劣效性、多中心、随机试验
Lancet Haematol. 2020 Sep;7(9):e640-e648. doi: 10.1016/S2352-3026(20)30227-1.
3
Secondary Immune Thrombocytopenic Purpura Triggered by COVID-19.由新型冠状病毒肺炎引发的继发性免疫性血小板减少性紫癜
Cureus. 2021 Apr 15;13(4):e14505. doi: 10.7759/cureus.14505.
4
Immune Thrombocytopenic Purpura in Patients with COVID-19.新型冠状病毒肺炎患者的免疫性血小板减少性紫癜
Eur J Case Rep Intern Med. 2020 Jun 9;7(7):001751. doi: 10.12890/2020_001751. eCollection 2020.
5
Intracranial haemorrhage among Chinese children with immune thrombocytopenia in a Hong Kong regional hospital.中国香港地区医院内患有免疫性血小板减少症的儿童的颅内出血。
Hong Kong Med J. 2013 Apr;19(2):129-34.
6
COVID-19 Presenting With a Challenging Combination of Thrombocytopenia and Thrombosis.新冠病毒肺炎表现为血小板减少症和血栓形成的挑战性组合。
J Med Cases. 2022 Apr;13(4):168-171. doi: 10.14740/jmc3886. Epub 2022 Mar 25.
7
Delayed onset of severe immune thrombocytopenia associated with COVID-19 pneumonia.与新型冠状病毒肺炎相关的严重免疫性血小板减少症延迟发作。
Respir Med Case Rep. 2021;34:101563. doi: 10.1016/j.rmcr.2021.101563. Epub 2021 Dec 2.
8
Immune thrombocytopenia and COVID-19: Case report and review of literature.免疫性血小板减少症与 COVID-19：病例报告及文献复习。
Lupus. 2021 Aug;30(9):1515-1521. doi: 10.1177/09612033211021161. Epub 2021 May 30.
9
Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine.Moderna mRNA-1273疫苗加强剂量后出现免疫性血小板减少症。
Cureus. 2022 Dec 23;14(12):e32873. doi: 10.7759/cureus.32873. eCollection 2022 Dec.
10
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.依鲁替尼治疗儿童慢性免疫性血小板减少症（PETIT2）的随机、多中心、安慰剂对照试验。
Lancet. 2015 Oct 24;386(10004):1649-58. doi: 10.1016/S0140-6736(15)61107-2. Epub 2015 Jul 28.
引用本文的文献
1
SARS-CoV-2 infection-induced immune thrombocytopenia: a systematic review of current reports.SARS-CoV-2 感染诱导的免疫性血小板减少症：当前报告的系统综述。
Ann Hematol. 2024 Oct;103(10):3921-3939. doi: 10.1007/s00277-024-05765-1. Epub 2024 Apr 23.
2
Immune Thrombocytopenic Purpura (ITP) Following Natural COVID-19 Infection.自然感染新冠病毒后发生的免疫性血小板减少性紫癜（ITP）
Cureus. 2022 Jul 5;14(7):e26582. doi: 10.7759/cureus.26582. eCollection 2022 Jul.
3
The Development of Immune Thrombocytopenia Due to COVID-19 Presenting as Menorrhagia.新型冠状病毒肺炎所致免疫性血小板减少症表现为月经过多的进展情况
Cureus. 2022 Apr 15;14(4):e24160. doi: 10.7759/cureus.24160. eCollection 2022 Apr.
4
COVID-19-A Trigger Factor for Severe Immune-Mediated Thrombocytopenia in Active Rheumatoid Arthritis.新冠病毒病——活动期类风湿关节炎严重免疫介导性血小板减少症的触发因素
Life (Basel). 2022 Jan 6;12(1):77. doi: 10.3390/life12010077.
5
Case Series: The Coexistence of Thrombocytopenia and Thromboembolism in COVID-19 Patients on ECMO: A Case Series and Literature Review.病例系列：接受体外膜肺氧合治疗的新冠肺炎患者血小板减少与血栓栓塞并存：病例系列及文献综述
Front Med (Lausanne). 2021 Sep 8;8:731352. doi: 10.3389/fmed.2021.731352. eCollection 2021.
6
Autoimmune complications of COVID-19.新型冠状病毒肺炎的自身免疫并发症
J Med Virol. 2022 Jan;94(1):54-62. doi: 10.1002/jmv.27292. Epub 2021 Aug 31.
7
A Case of Immune Thrombocytopenia After COVID-19 Infection.1例新型冠状病毒肺炎感染后免疫性血小板减少症病例
Cureus. 2021 Jun 22;13(6):e15843. doi: 10.7759/cureus.15843. eCollection 2021 Jun.
8
Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity.从 COVID-19 的角度看血小板；血小板减少症的病理生理学及其作为预后和治疗机会的意义。
Int Immunopharmacol. 2021 Oct;99:107995. doi: 10.1016/j.intimp.2021.107995. Epub 2021 Jul 21.
9
A systematic review of dermatologic manifestations among adult patients with COVID-19 diagnosis.对确诊为COVID-19的成年患者皮肤表现的系统评价。
Skin Health Dis. 2021 Jun;1(2):e20. doi: 10.1002/ski2.20. Epub 2021 Mar 19.
10
Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report.艾曲泊帕治疗与新型冠状病毒肺炎相关的严重免疫性血小板减少症和溶血性贫血：一例报告
Ther Adv Hematol. 2021 Apr 27;12:20406207211011353. doi: 10.1177/20406207211011353. eCollection 2021.
本文引用的文献
1
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.新型冠状病毒肺炎患者的凝血障碍与抗磷脂抗体
N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
2
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
3
Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.血小板减少症与严重的 2019 年冠状病毒病（COVID-19）感染相关：一项荟萃分析。
Clin Chim Acta. 2020 Jul;506:145-148. doi: 10.1016/j.cca.2020.03.022. Epub 2020 Mar 13.
4
American Society of Hematology 2019 guidelines for immune thrombocytopenia.美国血液学会 2019 年免疫性血小板减少症治疗指南。
Blood Adv. 2019 Dec 10;3(23):3829-3866. doi: 10.1182/bloodadvances.2019000966.
5
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.更新的原发性免疫性血小板减少症的调查和管理国际共识报告。
Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812.
6
Is there still a place for "old therapies" in the management of immune thrombocytopenia?在免疫性血小板减少症的治疗中，“传统疗法”是否仍有一席之地？
Rev Med Interne. 2016 Jan;37(1):43-9. doi: 10.1016/j.revmed.2015.08.007. Epub 2015 Oct 1.
7
Thrombocytopenia in patients with severe acute respiratory syndrome (review).重症急性呼吸综合征患者的血小板减少症（综述）
Hematology. 2005 Apr;10(2):101-5. doi: 10.1080/10245330400026170.
8
Impairment of bone marrow pre-B and B cells in MHV3 chronically-infected mice.MHV3慢性感染小鼠的骨髓前B细胞和B细胞受损。
Adv Exp Med Biol. 1995;380:193-5. doi: 10.1007/978-1-4615-1899-0_33.
Zotero 插件